AlphaMadera's AlphaVal page classifies Aehr Test Systems as a Cyclical & Capital-Intensive business and values it using Normalized Earnings × Cycle Multiple, then compares the result to the current market price to flag AEHR as undervalued, fairly valued, or overvalued.

What is Aehr Test Systems's fair value?

Fair value for AEHR comes from a Normalized Earnings × Cycle Multiple model -- the approach AlphaVal selected for this company's Cyclical & Capital-Intensive classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value AEHR?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. AEHR was classified as Cyclical & Capital-Intensive and is valued using Normalized Earnings × Cycle Multiple, built from AEHR's most recent reported fundamentals.

AEHR - Aehr Test Systems

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $132.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Cyclical & Capital-Intensive 80% confidence

Primary model: Normalized Earnings × Cycle Multiple

Valuation Signal Overvalued Strong

Trading 1503.1% above fair value

Current Price $87.21

Bear Case $4.08 95.3% downside ($4.08 - $87.21) / $87.21 = -95.3% $0.34 × 12x

Fair Value $5.44 93.8% downside ($5.44 - $87.21) / $87.21 = -93.8% $0.34 × 16x

Bull Case $6.80 92.2% downside ($6.80 - $87.21) / $87.21 = -92.2% $0.34 × 20x

Adjust Assumptions

Cycle P/E Multiple

16.0x

Normalized EPS

0.34$

Key Value Driver

Through-cycle normalized EPS ($0.34)

Terminal Value % of EV

Implied Market Multiple 256.5x

Market is pricing in (growth)

Plain-Language Summary

Using 7-year normalized EPS of $0.34 at a 16x cycle multiple, the base-case value is $5.44 per share. P/TBV cross-check: 14.3x.

Warnings

⚠ Price-to-book value of 14.3x is above the normal range for this type of business (0.7x-2.0x). The stock may already price in a strong cycle.

⚠ This stock is 41% below its 52-week high, with weak or declining earnings. That combination often signals real trouble, even though the valuation below is based on other fundamentals.

Key Risks

Standard 10-year DCF produces unreliable terminal values for cyclicals
'Cheap' P/E at cycle peak is the most common value trap — normalize first
Captive finance subsidiaries have different risk profiles from manufacturing